Immunomodulatory pharmaceutical compositions including a synthetic peptide and transforming growth factor beta

Abstract

The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.

What is claimed is: 
     
         1 . A pharmaceutical composition, comprising
 a synthetic peptide which is IFKKISRDKSVTIYL (SEQ ID NO: 5) or VKGKKVYVTLTCAFR (SEQ ID NO: 6) or YGQEDVDVIGLTFRR (SEQ ID NO: 7) or LPLLANNRERRGIAL (SEQ ID NO: 8) or DTNLASSTIIKEGID (SEQ ID NO: 9) or VTVDVNSSEK (SEQ ID NO: 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO: 20) or GEPITVTVSVTN (SEQ ID NO: 22) or IPVTIDVTDN (SEQ ID NO: 25); and an enhancer selected from the group consisting of: transforming growth factor beta (TGF-β), rapamycin, fingolimod (FTY720), and a sphingosine kinase 1 inhibitor.   
     
     
         2 . A pharmaceutical composition, comprising
 a synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO: 2) or VTVDVTNNTEKTVKK (SEQ ID NO: 3) or IFKKISRDKSVTIYL (SEQ ID NO: 5) or VKGKKVYVTLTCAFR (SEQ ID NO: 6) or YGQEDVDVIGLTFRR (SEQ ID NO: 7) or LPLLANNRERRGIAL (SEQ ID NO: 8) or DTNLASSTIIKEGID (SEQ ID NO: 9) or VTVDVNSSEK (SEQ ID NO: 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO: 20) or GEPITVTVSVTN (SEQ ID NO: 22) or IPVTIDVTDN (SEQ ID NO: 25); and an enhancer selected from the group consisting of: high molecular weight hyaluronic acid, IL-2, IL-5, all-trans retinoic acid, anti-CD3, anti-CD28, vitamin D3, dexamethasone, IL-10, idolamine-2,3-dioxygenase, cholera toxin B subunit, ovalbumin, Flt2L, sirolimus, anti-thymocyte globulin, and CTLA-4/Ig.   
     
     
         3 . A method of treating a patient suffering from an autoimmune disease, comprising
 administering to said patient a synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO: 2) or VTVDVTNNTEKTVKK (SEQ ID NO: 3) or IFKKISRDKSVTIYL (SEQ ID NO: 5) or VKGKKVYVTLTCAFR (SEQ ID NO: 6) or YGQEDVDVIGLTFRR (SEQ ID NO: 7) or LPLLANNRERRGIAL (SEQ ID NO: 8) or DTNLASSTIIKEGID (SEQ ID NO: 9) or VTVDVNSSEK (SEQ ID NO: 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO: 20) or GEPITVTVSVTN (SEQ ID NO: 22) or IPVTIDVTDN (SEQ ID NO: 25).   
     
     
         4 . A method of treating a patient suffering from an immune disease of the eye, comprising
 administering to said patient a synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO: 2) or VTVDVTNNTEKTVKK (SEQ ID NO: 3) or IFKKISRDKSVTIYL (SEQ ID NO: 5) or VKGKKVYVTLTCAFR (SEQ ID NO: 6) or YGQEDVDVIGLTFRR (SEQ ID NO: 7) or LPLLANNRERRGIAL (SEQ ID NO: 8) or DTNLASSTIIKEGID (SEQ ID NO: 9) or VTVDVNSSEK (SEQ ID NO: 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO: 20) or GEPITVTVSVTN (SEQ ID NO: 22) or IPVTIDVTDN (SEQ ID NO: 25).   
     
     
         5 . A method of treating a patient suffering from dysfunctional regulatory T-cells, comprising
 administering to said patient a synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO: 2) or VTVDVTNNTEKTVKK (SEQ ID NO: 3) or IFKKISRDKSVTIYL (SEQ ID NO: 5) or VKGKKVYVTLTCAFR (SEQ ID NO: 6) or YGQEDVDVIGLTFRR (SEQ ID NO: 7) or LPLLANNRERRGIAL (SEQ ID NO: 8) or DTNLASSTIIKEGID (SEQ ID NO: 9) or VTVDVNSSEK (SEQ ID NO: 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO: 20) or GEPITVTVSVTN (SEQ ID NO: 22) or IPVTIDVTDN (SEQ ID NO: 25).